Business
CEO Interview: Thalia’s RNA Therapeutics Strategy
Thalia Therapeutics plc announced the release of a video interview with its CEO, Dr. David Solomon, detailing the company's strategic shift towards high-value RNA therapeutics and its ongoing development of Nuvec®, a proprietary gene delivery system. The interview highlights Thalia's focus on opportunities within cardiovascular disease and oncology, aiming to address unmet medical needs with its innovative RNA-based treatments and delivery platform. Disclaimer*
About this update from Thalia Therapeutics Plc
[{"type":"text","content":"\n\n \n \n \n13 May 2026\n \nThalia Therapeutics plc\n \n(\"Thalia\" or the \"Company\")\n \nCEO Interview: Advancing Thalia's RNA Therapeutics Strategy\n \nThalia Therapeutics plc (AIM: THAT), a biotech company developing innovative RNA therapeutics, is pleased to announce the release of a new video interview with Chief Executive Officer, Dr David Solomon.\nIn the interview, Dr Solomon discusses the Company's strategic transition to Thalia Therapeutics, the rationale behind its increasing focus on high-value RNA therapeutics, the continued development of Nuvec®, and the opportunities the Company sees in cardiovascular disease and oncology.\nThe interview is available to watch via the Company's website at: https://investors.thaliatx.com/activity-updates\n \n- Ends -\n \nFor more information please contact:\n \n\n\n\n\nThalia Therapeutics plc\nDr David H Solomon, Chief Executive Officer\n\n\n \nVia Thalia Investor Hub\nhttps://investors.thaliatx.com/link/P4zkAe\n\n\n\n\nSP Angel Corporate Finance LLP\nNominated Adviser and Joint Broker\nMatthew Johnson/Jen Clarke (Corporate Finance)\nVadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)\n\n\nTel: +44 (0)20 3470 0470\n\n\n\n\nTurner Pope Investments (TPI) Limited\nJoint Broker\nAndy Thacker\nGuy McDougall \n\n\nTel: +44 (0)20 3657 0050\n\n\n\n\nNorthstar Communications\nInvestor relations and Communications\nSarah Hollins\n \nCohesion Bureau\nInvestor relations and Communications\nMary-Ann Chang\n\n\nTel: +44 (0)20 7183 2463\n \n \n \nTel: +44 (0)7483 284853\n \n \n \n\n\n\n\nAbout Thalia Therapeutics plc\n \nThalia Therapeutics plc is a pre-clinical biotech company focused on developing innovative RNA therapeutics and novel delivery systems to address high unmet needs in global healthcare.\n \nRNA therapeutics is one of the most rapidly growing therapeutic sectors that is set to impact the treatment of a wide range of diseases. Thalia Therapeutics is developing a wholly owned pipeline of novel RNA therapeutics for cardiovascular and other diseases, as well as developing Nuvec®, its proprietary gene delivery system, to further differentiate its therapeutic assets. \n \nNuvec® addresses multiple challenges associated with RNA therapeutics manufacturing and de...